Interestingly, while FXYD2 is downregulated in ccRCC, it is upregulated in other tumor types, such as colorectal, hepatocellular, and ovarian clear cell carcinomas, where its high expression correlates with advanced disease and poor prognosis [61]. The gene discussed is FXYD2; the disease is ovarian clear cell cancer.